Childhood-onset psoriatic onycho-pachydermo-periostitis treated successfully with infliximab

Watabe, Daisuke; Endoh, Koki; Maeda, Fumihiko; Akasaka, Toshihide; Endoh, Mikiya

doi:10.1684/ejd.2015.2616

Cited by 6 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristic features of periosteal reaction and erosions without involvement of the DIP joint were noted radiographically. 5 In 2015, a further paediatric case of POPP in an 8-year-old girl was published by Watabe et al 6…”

Section: Demographicsmentioning

confidence: 99%

Psoriatic Onycho-Pachydermo-Periostitis

Hesni

Khodatars

Rees

et al. 2021

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

Psoriatic onycho-pachydermo-periostitis (POPP) is an unfamiliar and poorly recognised condition first described in 1989 by Fournie et al. It is a variant of psoriatic arthritis comprising the triad of onycholysis, soft tissue thickening and radiographically apparent periostitis. Whilst typically affecting the great toe, any of the digits of the hands and feet may be affected. A ‘drumstick’ appearance to the digits of the foot is the most common clinical presentation and can be extremely painful. Nail changes are another hallmark of POPP and can be mistakenly diagnosed as fungal infection leading to lengthy periods of incorrect treatment. In this article, we will outline the clinical presentation, imaging features, pathogenesis and treatment options for POPP. Currently, the existence of POPP is not widely known. Awareness of this unusual condition will allow early appropriate treatment and can aid in the diagnosis of indeterminate seronegative disease.

show abstract

Section: Demographicsmentioning

confidence: 99%

Psoriatic Onycho-Pachydermo-Periostitis

Hesni

Khodatars

Rees

et al. 2021

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

show abstract

“…3,4 Moreover, delay in treatment or therapeutic choice may make a profound difference in the patient's QOL. [3][4][5] To date, three cases of POPP successfully treated with anti-tumour necrosis factor-a agents have been described. [3][4][5] In one case, complete relief of pain was obtained 10 days after the initial adalimumab treatment.…”

mentioning

confidence: 99%

“…[3][4][5] To date, three cases of POPP successfully treated with anti-tumour necrosis factor-a agents have been described. [3][4][5] In one case, complete relief of pain was obtained 10 days after the initial adalimumab treatment. 3 Conversely, joint fusion and phalangeal destruction occurred in the second patient despite treatment with infliximab.…”

mentioning

confidence: 99%

“…4 Recently, there has been a report of a patient with childhood-onset POPP who was resistant to adalimumab but was successfully treated with infliximab. 5 We chose infliximab as first-line therapy to prevent the finger joints from being permanently disabled. As a result, Letters to the Editors in our patient there were not only remarkable improvements in clinical appearance but also in her recovery of functional capacity at a phenomenal speed.…”

mentioning

confidence: 99%

See 1 more Smart Citation